Dioscin Alleviates Diabetic Kidney Disease via Activation of the Nrf2/HO-1 Signaling Axis
Diabetes, Metabolic Syndrome and Obesity · 2026-10 · Volume 19 · 1-13
DOI: 10.2147/dmso.s590914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2026-10. Verfasst von Yan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhe…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang, People's Republic of China.
ORCID-Profile: Yan Li, Xiaoyun Zhang
Zitieren
APA
Li, Y., Zhang, X., Zhang, M., Li, S., Chen, Y., & Zhang, L. (2026). Dioscin Alleviates Diabetic Kidney Disease via Activation of the Nrf2/HO-1 Signaling Axis. Diabetes, Metabolic Syndrome and Obesity, Volume 19, 1-13. https://doi.org/10.2147/dmso.s590914
Vancouver
Li Y, Zhang X, Zhang M, Li S, Chen Y, Zhang L. Dioscin Alleviates Diabetic Kidney Disease via Activation of the Nrf2/HO-1 Signaling Axis. Diabetes, Metabolic Syndrome and Obesity. 2026;Volume 19:1-13. doi:10.2147/dmso.s590914
BibTeX
@article{Li2026,
author = {Li, Yan and Zhang, Xiaoyun and Zhang, Mansheng and Li, Subo and Chen, Yubo and Zhang, Li},
title = {Dioscin Alleviates Diabetic Kidney Disease via Activation of the Nrf2/HO-1 Signaling Axis},
journal = {Diabetes, Metabolic Syndrome and Obesity},
year = {2026},
volume = {Volume 19},
pages = {1--13},
doi = {10.2147/dmso.s590914}
}
EUVIMED